Business
bioAffinity Technologies Announces Pricing of $3.25 Million Offering
SAN ANTONIO, May 06, 2025--bioAffinity Technologies announces the pricing of a best efforts offering of securities for aggregate gross proceeds of $3.25 million.
About this update from Bioaffinity Technologies, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":201,"url":"https://media.zenfs.com/en/business-wire.com/844e2e3b6075cc6a2e2ccb2780248c4b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CxJSn9iUDjETyMlsQOK7Bg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQwMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/844e2e3b6075cc6a2e2ccb2780248c4b","width":480,"height":201}},"lazy":false},{"type":"text","content":"SAN ANTONIO, May 06, 2025--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has priced a best efforts offering of securities as described below for aggregate gross proceeds to the Company of $3.25 million, before deducting agent fees and other estimated expenses payable by the company.","length":438,"tagName":"p"},{"type":"text","content":"The offering consists of 10,156,250 shares (the "Shares") of our Common Stock (or pre-funded warrants), together with warrants to initially purchase up to 15,234,375 shares of Common Stock, (the "May 2025 Warrants"). The combined public offering price for each share of common stock (or pre-funded warrant) and accompanying May 2025 Warrant is $0.32.","length":370,"tagName":"p"},{"type":"text","content":"The closing of the offering is expected to occur on or about May 7, 2025, subject to the satisfaction of customary closing conditions.","length":134,"tagName":"p"},{"type":"text","content":"WallachBeth Capital, LLC is acting as sole placement agent for the offering.","length":76,"tagName":"p"},{"type":"text","content":"This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.","length":310,"tagName":"p"},{"type":"text","content":"The securities described above are being offered by the Company pursuant to a registration statement on Form S-1 (File No. 333-286921), as amended, previously filed and declared effective by the Securities and Exchange Commission (the "SEC"). This...